Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPD | P32754 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432724 | 0.93 | CYP19A1 (0.49) | MGMTCYP19A1MEN1KMT2ACYP11B1 | |
| SCHEMBL2434879 | 0.93 | CYP19A1 (0.51) | MGMTCYP19A1MEN1KMT2ACYP11B1 | |
| SCHEMBL21685240 | 0.91 | MGMT (0.53) | MGMTCYP19A1MEN1KMT2ACYP11B1 | |
| SCHEMBL34476061 | 0.90 | CYP19A1 (0.46) | MGMTCYP19A1MEN1KMT2ACYP11B1 | |
| SCHEMBL19320318 | 0.90 | CYP19A1 (0.49) | MGMTCYP19A1MEN1KMT2ACYP11B1 | |
| SCHEMBL34475063 | 0.87 | MEN1 (0.60) | MGMTCYP19A1MEN1KMT2ACYP11B1 | |
| SCHEMBL17739312 | 0.85 | HPD (0.47) | MGMTCYP19A1KMT2AMAPTHPD | |
| SCHEMBL34475584 | 0.85 | MEN1 (0.49) | MGMTCYP19A1MEN1KMT2AMAPT | |
| SCHEMBL15013285 | 0.83 | MAPT (0.55) | MGMTCYP19A1MEN1KMT2ACYP11B1 | |
| SCHEMBL34476251 | 0.83 | MAPT (0.45) | MGMTCYP19A1MEN1KMT2ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423457-B1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-10689325-B2 | Process for the preparation of an antibody-rifamycin conjugate | GENENTECH, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689325-B2 | Process for the preparation of an antibody-rifamycin conjugate | GENENTECH, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3004162-B1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10570192-B2 | Anti-wall teichoic antibodies and conjugates | GENENTECH, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190270695-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270695-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10336683-B2 | Process for the preparation of an antibody-rifamycin conjugate | GENENTECH, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336683-B2 | Process for the preparation of an antibody-rifamycin conjugate | GENENTECH, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3423457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | H. Hoffnabb-La Roche Ag (CH) | 2019-01-09 | — | — | EP | disclosed |
| EP-3226908-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| WO-2016090040-A9 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2016090040-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-3004162-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | Genentech, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014194247-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336683-B2 | Process for the preparation of an antibody-rifamycin conjugate | FUCA2, MRPL21, FNTB | MGMT 2820/4885CYP19A1 1102/4885MEN1 1944/4885 |
| US-20190270695-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | FUCA2, MRPL21, FNTB | MGMT 2820/4885CYP19A1 1102/4885MEN1 1944/4885 |
| US-10689325-B2 | Process for the preparation of an antibody-rifamycin conjugate | FUCA2, MRPL21, FNTB | MGMT 2820/4885CYP19A1 1102/4885MEN1 1944/4885 |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | MGMT 4099/4885CYP19A1 4528/4885MEN1 3388/4885 |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | MGMT 4099/4885CYP19A1 4528/4885MEN1 3388/4885 |
| US-10570192-B2 | Anti-wall teichoic antibodies and conjugates | STT3A, STT3B, DDOST | MGMT 4099/4885CYP19A1 4528/4885MEN1 3388/4885 |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | FUCA2, MRPL21, FNTB | MGMT 2820/4885CYP19A1 1102/4885MEN1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.